These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 22988063

  • 1. Effects of the novel α7 nicotinic acetylcholine receptor agonist ABT-107 on sensory gating in DBA/2 mice: pharmacodynamic characterization.
    Radek RJ, Robb HM, Stevens KE, Gopalakrishnan M, Bitner RS.
    J Pharmacol Exp Ther; 2012 Dec; 343(3):736-45. PubMed ID: 22988063
    [Abstract] [Full Text] [Related]

  • 2. The selective nicotinic acetylcholine receptor alpha7 agonist JN403 is active in animal models of cognition, sensory gating, epilepsy and pain.
    Feuerbach D, Lingenhoehl K, Olpe HR, Vassout A, Gentsch C, Chaperon F, Nozulak J, Enz A, Bilbe G, McAllister K, Hoyer D.
    Neuropharmacology; 2009 Jan; 56(1):254-63. PubMed ID: 18793655
    [Abstract] [Full Text] [Related]

  • 3. In vitro pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107.
    Malysz J, Anderson DJ, Grønlien JH, Ji J, Bunnelle WH, Håkerud M, Thorin-Hagene K, Ween H, Helfrich R, Hu M, Gubbins E, Gopalakrishnan S, Puttfarcken PS, Briggs CA, Li J, Meyer MD, Dyhring T, Ahring PK, Nielsen EØ, Peters D, Timmermann DB, Gopalakrishnan M.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):863-74. PubMed ID: 20504915
    [Abstract] [Full Text] [Related]

  • 4. In vivo pharmacological characterization of a novel selective alpha7 neuronal nicotinic acetylcholine receptor agonist ABT-107: preclinical considerations in Alzheimer's disease.
    Bitner RS, Bunnelle WH, Decker MW, Drescher KU, Kohlhaas KL, Markosyan S, Marsh KC, Nikkel AL, Browman K, Radek R, Anderson DJ, Buccafusco J, Gopalakrishnan M.
    J Pharmacol Exp Ther; 2010 Sep 01; 334(3):875-86. PubMed ID: 20504913
    [Abstract] [Full Text] [Related]

  • 5. Clozapine improves deficient inhibitory auditory processing in DBA/2 mice, via a nicotinic cholinergic mechanism.
    Simosky JK, Stevens KE, Adler LE, Freedman R.
    Psychopharmacology (Berl); 2003 Feb 01; 165(4):386-96. PubMed ID: 12459928
    [Abstract] [Full Text] [Related]

  • 6. Alpha4beta2 nicotinic receptor stimulation contributes to the effects of nicotine in the DBA/2 mouse model of sensory gating.
    Radek RJ, Miner HM, Bratcher NA, Decker MW, Gopalakrishnan M, Bitner RS.
    Psychopharmacology (Berl); 2006 Jul 01; 187(1):47-55. PubMed ID: 16767415
    [Abstract] [Full Text] [Related]

  • 7. Stimulation of the alpha4beta2 nicotinic receptor by 5-I A-85380 improves auditory gating in DBA/2 mice.
    Wildeboer KM, Stevens KE.
    Brain Res; 2008 Aug 11; 1224():29-36. PubMed ID: 18582447
    [Abstract] [Full Text] [Related]

  • 8. Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice.
    Schreiber R, Dalmus M, De Vry J.
    Psychopharmacology (Berl); 2002 Jan 11; 159(3):248-57. PubMed ID: 11862357
    [Abstract] [Full Text] [Related]

  • 9. The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
    Hajós M, Hurst RS, Hoffmann WE, Krause M, Wall TM, Higdon NR, Groppi VE.
    J Pharmacol Exp Ther; 2005 Mar 11; 312(3):1213-22. PubMed ID: 15523001
    [Abstract] [Full Text] [Related]

  • 10. Activation of α4β2*/α6β2* nicotinic receptors alleviates anxiety during nicotine withdrawal without upregulating nicotinic receptors.
    Yohn NL, Turner JR, Blendy JA.
    J Pharmacol Exp Ther; 2014 May 11; 349(2):348-54. PubMed ID: 24627467
    [Abstract] [Full Text] [Related]

  • 11. Effects of nicotine vary across two auditory evoked potentials in the mouse.
    Metzger KL, Maxwell CR, Liang Y, Siegel SJ.
    Biol Psychiatry; 2007 Jan 01; 61(1):23-30. PubMed ID: 16497274
    [Abstract] [Full Text] [Related]

  • 12. EVP-6124, a novel and selective α7 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of α7 nicotinic acetylcholine receptors.
    Prickaerts J, van Goethem NP, Chesworth R, Shapiro G, Boess FG, Methfessel C, Reneerkens OA, Flood DG, Hilt D, Gawryl M, Bertrand S, Bertrand D, König G.
    Neuropharmacology; 2012 Feb 01; 62(2):1099-110. PubMed ID: 22085888
    [Abstract] [Full Text] [Related]

  • 13. The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents.
    Boess FG, De Vry J, Erb C, Flessner T, Hendrix M, Luithle J, Methfessel C, Riedl B, Schnizler K, van der Staay FJ, van Kampen M, Wiese WB, Koenig G.
    J Pharmacol Exp Ther; 2007 May 01; 321(2):716-25. PubMed ID: 17308038
    [Abstract] [Full Text] [Related]

  • 14. ABT-089, but not ABT-107, ameliorates nicotine withdrawal-induced cognitive deficits in C57BL6/J mice.
    Yildirim E, Connor DA, Gould TJ.
    Behav Pharmacol; 2015 Apr 01; 26(3):241-8. PubMed ID: 25426579
    [Abstract] [Full Text] [Related]

  • 15. Nicotinic modulation of auditory evoked potential electroencephalography in a rodent neurodevelopmental model of schizophrenia.
    Kohlhaas KL, Robb HM, Roderwald VA, Rueter LE.
    Biochem Pharmacol; 2015 Oct 15; 97(4):482-487. PubMed ID: 26032639
    [Abstract] [Full Text] [Related]

  • 16. Role of α7 nicotinic acetylcholine receptors in regulating tumor necrosis factor-α (TNF-α) as revealed by subtype selective agonists.
    Li J, Mathieu SL, Harris R, Ji J, Anderson DJ, Malysz J, Bunnelle WH, Waring JF, Marsh KC, Murtaza A, Olson LM, Gopalakrishnan M.
    J Neuroimmunol; 2011 Oct 28; 239(1-2):37-43. PubMed ID: 21911260
    [Abstract] [Full Text] [Related]

  • 17. The smoking cessation drug varenicline improves deficient P20-N40 inhibition in DBA/2 mice.
    Wildeboer-Andrud KM, Stevens KE.
    Pharmacol Biochem Behav; 2011 Nov 28; 100(1):17-24. PubMed ID: 21763340
    [Abstract] [Full Text] [Related]

  • 18. ABT-594 [(R)-5-(2-azetidinylmethoxy)-2-chloropyridine]: a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors: II. In vivo characterization.
    Bannon AW, Decker MW, Curzon P, Buckley MJ, Kim DJ, Radek RJ, Lynch JK, Wasicak JT, Lin NH, Arnold WH, Holladay MW, Williams M, Arneric SP.
    J Pharmacol Exp Ther; 1998 May 28; 285(2):787-94. PubMed ID: 9580627
    [Abstract] [Full Text] [Related]

  • 19. Characterization of 2-[[4-fluoro-3-(trifluoromethyl)phenyl]amino]-4-(4-pyridinyl)-5-thiazolemethanol (JNJ-1930942), a novel positive allosteric modulator of the {alpha}7 nicotinic acetylcholine receptor.
    Dinklo T, Shaban H, Thuring JW, Lavreysen H, Stevens KE, Zheng L, Mackie C, Grantham C, Vandenberk I, Meulders G, Peeters L, Verachtert H, De Prins E, Lesage AS.
    J Pharmacol Exp Ther; 2011 Feb 28; 336(2):560-74. PubMed ID: 21084390
    [Abstract] [Full Text] [Related]

  • 20. JN403, in vitro characterization of a novel nicotinic acetylcholine receptor alpha7 selective agonist.
    Feuerbach D, Nozulak J, Lingenhoehl K, McAllister K, Hoyer D.
    Neurosci Lett; 2007 Apr 06; 416(1):61-5. PubMed ID: 17314009
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.